Contact this trialFirst, we need to learn more about you.
Chemotherapy
NRC-2694-A + Paclitaxel for Head and Neck Cancer
Recruiting3 awardsPhase 2
Baltimore, Maryland
This trial will test the effects of a new drug, NRC-2694-A, on patients with head and neck cancer that has progressed after immunotherapy. The trial will enroll approximately 46 patients. The target response rate is 50%.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.